Macroprolactinomas: CT evaluation of reduction of tumor size after medical treatment

Neuroradiology - Tập 23 - Trang 123-126 - 1982
G. Scotti1,2, G. Scialfa1,2, S. Pieralli1,2, P. G. Chiodini1,2, B. Spelta1,2, D. Dallabonzana1,2
1Department of Neuroradiology, Ente Ospedaliero Niguarda, Ospedale Maggiore, Milan, Italy
2Department of Endocrinology, Ente Ospedaliero Niguarda, Ospedale Maggiore, Milan, Italy

Tóm tắt

Thirty patients with macroprolactinomas were treated with dopaminergic drugs from a minimum of 4 months to a maximum of 6 years. Tumor size was evaluated with serial CT during treatment; serum prolactin levels and visual fields were also assessed at the same time. Reduction of PRL levels was found in 28 patients of whom 20 also had marked reduction of tumor volume on CT. Two patterns of reduction of size of tumor in relation with time were observed. In one, tumor shrinkage occurred rapidly in the first month and even in the first week after starting treatment. In the other pattern the tumor reduced in size only after some months of treatment. It is proposed that all patients with macroprolactinomas should be treated medically before considering surgery. A radiological diagnostic and research protocol is proposed, including scout views, thin slices, coronal sections, objective measurement of tumor size and density, serial CTs at 7, 21, 45 days, 6 months and then every year after the beginning of treatment.

Tài liệu tham khảo

Del Pozo E, Brun del ReP, Varga L, Friesen H (1972) The inhibition of prolactin secretion in man by CB-154 (2-Br-α-ergocryptine). J Clin Endocrinol Metab 35:768–771 Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Silvestrini F (1972) Inhibitory effect of L-Dopa on GH release in acromegalic patients. J Clin Endocrinol Metab 35:941–943 Wolfman NT, Boehnke M (1978) The use of coronal sections in evaluating lesions of the sellar and parasellar regions. J Comput Assist Tomogr 2:308–313 Naidich TP, Pinto RS, Kushner MS, Lin JP, Kricheff I, Leeds NE, Chase NE (1976) Evaluation of sellar and parasellar masses by computed tomography. Radiology 120:91–99 Jacobs L, Weisberg LA, Kinkel WR (1980) Computerized tomography of the orbit and sella turcica. Raven Press, New York Smaltino F, Bernini FP, Muras I (1980) Computed tomography for diagnosis of empty sella associated with enhancing pituitary microadenoma. J Comput Assist Tomogr 4:592–599 Chiodini PG, Liuzzi A, Cozzi R, Verde G, Silvestrini F, Marsili MT, Horowski R, Passerini A, Luccarelli G, Borghi PG (1978) Size reduction of a prolactin secreting adenoma during a long term treatment with a dopamine agonist Lisuride. International Symposium on Pituitary Microadenomas (Serono Symposia), Milan, 12–14 October, Abstract 64 Chiodini PG, Liuzzi A, Cozzi R, Verde G, Oppizzi G, Dellabonzana D, Spelta B, Silvestrini F, Marsili MT (1981) Macroprolactinomas and GH secreting adenomas: medical treatment. International Symposium on pituitary hormones and related peptides from cells biology to clinical applications, Republic of San Marino, 25–27 May, Abstract 33 Pawlikowski M (1978) Attempt at pharmacological treatment of the pituitary tumor with bromocriptine. Endocrynol Pol 29:413–416 Eversmann T, Fahlbush R, Rjosk KH, Vonwerder K (1979) Persisting suppression of prolactin secretion after long term treatment with bromocriptine in patients with prolactinomas. Acta Endocrinol 92:413–427 Clark BJ, Fluckiger E, Loew DM, Vigouret JM (1978) How does bromocriptine work? Triangle 17:21–31 Pavdalova I, Dablac A (1972) Lysenil, a new antiserotonin agent. Res Clin Stud Headache 3:325–334